---
title: "Nurtec ODT (rimegepant) in acute treatment of migraine: Safety questions"
description: "Safety questions on Nurtec ODT (rimegepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Safety evidence. Questions: What are the most common side effects of Nurtec ODT for acute migraine? What are the long-term side effects of Nurtec ODT for acute migraine? What side effects did Nurtec ODT cause in triptan-unsuitable patients (trial 406)? Can Nurtec ODT be used in patients with cardiovascular risk factors? 1 further question follow. 5 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nurtec ODT (rimegepant) in acute treatment of migraine: Safety questions

Manufacturer: Pfizer Inc  
Prescribing information: [Nurtec ODT](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036)

Safety questions that apply to every indication of Nurtec ODT are on [Nurtec ODT (rimegepant), all indications: Safety](https://www.evicenter.com/medical-information/nurtec-odt/safety).

## Side effects

<a id="nurtec-side-effects"></a>

### What are the most common side effects of Nurtec ODT for acute migraine?

> “The most common adverse reaction in Study 1 was nausea (2% in patients who received NURTEC ODT compared to 0.4% of patients who received placebo).”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=The%20most%20common%20adverse%20reaction,of%20patients%20who%20received%20placebo%29.)

> “Hypersensitivity, including dyspnea and severe rash, occurred in less than 1% of patients treated with NURTEC ODT [see Contraindications (4) and Warnings and Precautions (5.1)].”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Hypersensitivity%2C%20including%20dyspnea%20and%20severe,and%20Warnings%20and%20Precautions%20%285.1%29%5D.)

> “Most common
> AEs in trial 303<sup>2</sup>	Nurtec ODT
> (n=682)	Placebo
> (n=693)
> Nausea	11 (2%)	3 (<1%)
> Urinary tract infection	10 (1%)	4 (1%)
> Dizziness	6 (1%)	7 (1%)”

Source: [NURTEC ODT: Acute Pivotal Trial, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-pivotal-trial#:~:text=Most%20common,7%20%281%25%29)

> “<1% of patients discontinued treatment with Nurtec ODT<sup>2</sup>”

Source: [NURTEC ODT: Acute Pivotal Trial, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-pivotal-trial#:~:text=%3C1%25%20of%20patients%20discontinued%20treatment%20with%20Nurtec)

Note: Single 75 mg dose of Nurtec ODT compared with placebo in trial 303 (the label's Study 1). The HCP page table columns are Nurtec ODT (n=682) and placebo (n=693). The label reports adverse reaction rates for preventive treatment separately; this answer quotes the acute-treatment rates.

<a id="nurtec-long-term-side-effects"></a>

### What are the long-term side effects of Nurtec ODT for acute migraine?

> “Long-term safety was assessed in an open-label extension study using a different oral dosage form of rimegepant. That study evaluated 1,798 patients, dosing intermittently for up to one year, including 1,131 patients who were exposed to rimegepant 75 mg for at least 6 months, and 863 who were exposed for at least one year, all of whom treated an average of at least two migraine attacks per month.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Long%2Dterm%20safety%20was%20assessed%20in,two%20migraine%20attacks%20per%20month.)

> “Evaluation of the long-term safety profile of rimegepant 75 mg (tablet) as acute treatment for migraine<sup>1*</sup>”

Source: [NURTEC ODT: Acute Long-Term Safety Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-long-term-safety-study#:~:text=Evaluation%20of%20the%20long%2Dterm%20safety,%28tablet%29%20as%20acute%20treatment%20for)

> “Most AEs were mild to
> moderate through 52 weeks<sup>1</sup>	PRN 2-8
> (n=1033)	PRN 9-14
> (n=481)
> AEs leading to discontinuation	24 (2.3%)	16 (3.3%)
> AEs reported in ≥2% of patients overall
> Upper respiratory tract infection 	108 (10.5%)	38 (7.9%)
> Nasopharyngitis	72 (7%)	  41 (8.5%)
> Sinusitis	57 (5.5%)	28 (5.8%)
> Urinary tract infection 	40 (3.9%)	21 (4.4%)
> Influenza	49 (4.7%)	9 (1.9%)
> Back pain	36 (3.5%)	14 (2.9%)
> Bronchitis	35 (3.4%)	14 (2.9%)
> Nausea	33 (3.2%)	 15 (3.1%)
> Dizziness	26 (2.5%)	13 (2.7%)
> Arthralgia	25 (2.4%)	9 (1.9%)”

Source: [NURTEC ODT: Acute Long-Term Safety Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-long-term-safety-study#:~:text=Most%20AEs%20were%20mild%20to,9%20%281.9%25%29)

> “This study evaluated an oral formulation of rimegepant that is bioequivalent to Nurtec ODT.<sup>3</sup>”

Source: [NURTEC ODT: Acute Long-Term Safety Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-long-term-safety-study#:~:text=This%20study%20evaluated%20an%20oral,that%20is%20bioequivalent%20to%20Nurtec)

> “PRN 2–8: patients with a self-reported history of 2–8 moderate to severe migraine attacks per month who treated migraine attacks of any severity (mild, moderate, or severe headache pain intensity) as needed with up to 1 rimegepant 75 mg oral tablet per calendar day for 52 weeks. PRN 9-14: patients with a self-reported history of 9-14 moderate to severe migraine attacks per month who treated migraine attacks of any severity (mild, moderate, or severe headache pain intensity) as needed with up to 1 rimegepant tablet per calendar day for 52 weeks.”

Source: [NURTEC ODT: Acute Long-Term Safety Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-long-term-safety-study#:~:text=PRN%202%E2%80%938%3A%20patients%20with%20a,rimegepant%20tablet%20per%20calendar%20day%20for%2052%20weeks.)

> “Trial 201 also included a preventive treatment arm (n=286), in which patients took rimegepant 75 mg every other day plus up to 1 daily dose as needed on nonscheduled days. Preventive treatment arm data are excluded from this presentation of acute treatment results.<sup>1</sup>”

Source: [NURTEC ODT: Acute Long-Term Safety Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-long-term-safety-study#:~:text=Trial%20201%20also%20included%20a,this%20presentation%20of%20acute%20treatment)

Note: Open-label study (trial 201) without a placebo group; table columns are the PRN 2-8 group (n=1033) and the PRN 9-14 group (n=481), each treating attacks as needed for up to 52 weeks.

<a id="nurtec-triptan-unsuitable-side-effects"></a>

### What side effects did Nurtec ODT cause in triptan-unsuitable patients (trial 406)?

> “AE, n (%)<sup>1,2</sup>	
> Nurtec ODT<sup>1,2</sup>
> (n=295)
> 	Placebo<sup>1,2</sup>
> (n=290)
> Any AE
> AE related to study drug	37 (12.5%)
> 10 (3.4%)	35 (12.1%)
> 10 (3.4%)
> Mild AE
> Moderate AE
> Severe AE
> Serious AE<sup>¶</sup>	31 (10.5%)
> 6 (2.0%)
> 0
> 0	19 (6.6%)
> 15 (5.2%)
> 1 (0.3%)
> 0
> AEs of interest
> Hypertension
> Raynaud’s phenomenon	
> 1 (0.3%)
> 1 (0.3%)	
> 0
> 0
>
>
> AEs occurring in ≥1% of treatment participants<sup>#</sup>: nasopharyngitis 1.7% (Nurtec ODT) vs 1.0% (placebo)<sup>1,2</sup>
> No serious AEs were reported in the study; most AEs were mild<sup>1,2</sup>
> AE frequency was similar across treatments: 12.5% (Nurtec ODT) vs 12.1% (placebo)<sup>1,2</sup>”

Source: [NURTEC ODT: Acute Triptan Unsuitable Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-triptan-unsuitable-study#:~:text=AE%2C%20n,12.5%25%20%28Nurtec%20ODT%29%20vs%2012.1%25)

> “#Additional AEs occurred in <1% of patients: upper abdominal pain 0.7% (Nurtec ODT) vs 0.3% (placebo), nausea 0.7% (Nurtec ODT) vs 0.3% (placebo), headache 0.7% (Nurtec ODT) vs 0.3% (placebo), dysmenorrhea 0.7% (Nurtec ODT) vs 0.3% (placebo), dizziness 0.7% (Nurtec ODT) vs 0% (placebo).<sup>4</sup>”

Source: [NURTEC ODT: Acute Triptan Unsuitable Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-triptan-unsuitable-study#:~:text=%23Additional%20AEs%20occurred%20in%20%3C1%25,0.7%25%20%28Nurtec%20ODT%29%20vs%200%25)

Note: Trial 406 compared Nurtec ODT (n=295) with placebo (n=290) in adults unsuitable for triptans. In each block of the table, the row labels are listed first, followed by the Nurtec ODT values in the same order and then the placebo values. Trial 406 is not described in the Prescribing Information.

## Safety evidence

<a id="nurtec-cardiovascular-risk"></a>

### Can Nurtec ODT be used in patients with cardiovascular risk factors?

> “Not contraindicated in patients with stable cardiovascular disease or risk factors”

Source: [NURTEC ODT: Acute Pivotal Trial, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-pivotal-trial#:~:text=Not%20contraindicated%20in%20patients%20with%20stable%20cardiovascular%20disease%20or%20risk%20factors)

> “NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components. Reactions have included anaphylaxis and delayed serious hypersensitivity [see Warnings and Precautions (5.1)].”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=NURTEC%20ODT%20is%20contraindicated%20in,%5Bsee%20Warnings%20and%20Precautions%20%285.1%29%5D.)

> “Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including NURTEC ODT, in the postmarketing setting.
>
> Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. NURTEC ODT was discontinued in many of the reported cases.
>
> Monitor patients treated with NURTEC ODT for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of NURTEC ODT is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Development%20of%20hypertension%20and%20worsening,blood%20pressure%20is%20inadequately%20controlled.)

> “Post hoc subgroup analysis: AEs in patients with CV risk factors<sup>5</sup>
>  	Number of CV risk factors
>  	0
> (n=1065)	1
> (n=518)	≥2
> (n=217)
> Patients with ≥1 AE	635 (59.6%)	318 (61.4%)	135 (62.2%)
> AEs leading to discontinuation	 20 (1.9%)	16 (3.1%)	12 (5.5%)
> Serious AEs	29 (2.7%)	13 (2.5%)	5 (2.3%)
> AEs related to rimegepant 75 mg	217 (20.4%)	108 (20.8%)	35 (16.1%)
> AEs reported in ≥5% of patients overall	 	 	 
> Upper respiratory tract infection 	98 (9.2%)	39 (7.5%)	21 (9.7%)
> Nasopharyngitis	71 (6.7%)	42 (8.1%)	9 (4.1%)
> Sinusitis	58 (5.4%)	28 (5.4%)	6 (2.8%)
> Limitations of the analysis
> Patients with uncontrolled, unstable, or recently diagnosed CVD were excluded from the study<sup>5</sup>
> Trial 201 was neither designed nor powered to evaluate major cardiovascular AEs in patients treated with rimegepant 75 mg
> Small subgroup size limits any generalization of the data”

Source: [NURTEC ODT: Acute Long-Term Safety Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-long-term-safety-study#:~:text=Post%20hoc%20subgroup%20analysis%3A%20AEs,any%20generalization%20of%20the%20data)

> “<sup>§</sup>CV risk factors included uncontrolled hypertension, treatment for hypertension, history of diabetes, current smoker, treatment with a statin, and family history of CAD.<sup>5</sup>”

Source: [NURTEC ODT: Acute Long-Term Safety Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-long-term-safety-study#:~:text=risk%20factors%20included%20uncontrolled%20hypertension%2C,statin%2C%20and%20family%20history%20of)

Note: The statement that Nurtec ODT is not contraindicated is from the acute pivotal trial page of the Nurtec HCP site, which gives no reference for it; the label lists hypersensitivity as its only contraindication. The subgroup data are a post hoc analysis of open-label trial 201 with no placebo group, in patients with cardiovascular risk factors; the trial excluded uncontrolled, unstable, or recently diagnosed cardiovascular disease. The subgroups add up to the 1,800 patients of the trial 201 overall population, which includes 286 patients who took rimegepant 75 mg every other day plus as needed for 12 weeks (the preventive treatment arm).

<a id="nurtec-with-preventive-medications"></a>

### Can Nurtec ODT be taken with migraine preventive medications?

> “Approximately 14% of patients were taking preventive medications for migraine at baseline. None of the patients in Study 1 were on concomitant preventive medication that act on the CGRP pathway.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Approximately%2014%25%20of%20patients%20were,act%20on%20the%20CGRP%20pathway.)

> “The safety of rimegepant 75 mg was assessed in patients taking certain concomitant preventive medications for migraine<sup>6</sup>”

Source: [NURTEC ODT: Acute Long-Term Safety Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-long-term-safety-study#:~:text=The%20safety%20of%20rimegepant%2075,certain%20concomitant%20preventive%20medications%20for)

> “Prespecified subgroup analysis: On-treatment AEs by use of preventives<sup>6</sup>
>  	Using Preventives<sup>6</sup>
> 243 (13.5%)	Not Using Preventives<sup>6</sup>
> 1557 (86.5%)
> Serious AE<sup>6</sup>	11 (4.5%)	36 (2.3%)
> AEs leading to discontinuation<sup>6</sup>	11 (4.5%)	37 (2.4%)
> AEs reported in ≥2% of patients overall
> Upper respiratory tract infection 	18 (7.4%)	140 (9.0%) 
> Nasopharyngitis	19 (7.8%)	103 (6.6%)
> Sinusitis	17 (7.0%)	 75 (4.8%)
> Urinary tract infection 	13 (5.3%)	56 (3.6%)
> Influenza	7 (2.9%)  	52 (3.3%)
> Back pain	13 (5.3%)	43 (2.8%)
> Bronchitis	11 (4.5%)	42 (2.7%)
> Nausea	8 (3.3%)	43 (2.8%)
> Dizziness	8 (3.3%) 	34 (2.2%)
> Arthralgia	5 (2.1%)	31 (2.0%)
>
> Concomitant preventive medications taken by patients in trial 201 included: anticonvulsants, antidepressants, beta blockers, botulinum toxin, calcium channel antagonists, NSAIDs.<sup>6</sup>
>
> Limitations:
> Prespecified subgroup analysis from an open-label safety study, not powered to determine differences between groups and should be interpreted with caution
> The concomitant preventive subgroup was relatively small, limiting detection of rare safety events
> While a small subgroup of patients receiving preventive CGRP biologics was included after a protocol amendment, safety data for concomitant use with these agents remain limited”

Source: [NURTEC ODT: Acute Long-Term Safety Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-long-term-safety-study#:~:text=Prespecified%20subgroup%20analysis%3A%20On%2Dtreatment%20AEs,with%20these%20agents%20remain%20limited)

Note: The subgroup data are a prespecified analysis of open-label trial 201 with no placebo group. The subgroups add up to the 1,800 patients of the trial 201 overall population, which includes 286 patients who took rimegepant 75 mg every other day plus as needed for 12 weeks (the preventive treatment arm).

## Related pages
- [Medical information: Nurtec ODT (rimegepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/clinical-trials)
- [Dosing and administration](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/guidelines)
